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Abstract 
 
Purpose    To assess the diversity, application, analysis and interpretation of patient reported 
outcomes (PROs) in asthma clinical trials.  
 
Methods    We critically appraised the use of asthma-specific PROs in 87 randomised controlled 
trials (RCTs) of inhaled asthma medications published during 1985 to 2006.  
 
Results    79 RCTs reported PROs, of which 78 (99%) assessed symptom scores and seven (9%) 
assessed asthma quality of life scores. Only eight (10%) used validated instruments and five 
(6%) provided clinical interpretation of scores. Due to heterogeneity in the reporting of 
symptom measures it is not possible to determine how many discrete symptom assessment 
instruments have been used. Only 26 (33%) of the RCTs that measured symptom scores reported 
the scores for follow up. Limited improvement occurred over time: fewer than 30% of the RCTs 
used validated PRO measures in any individual year. 
 
Conclusion   Numerous validated PRO instruments are available but it is unclear why few are 
used in asthma clinical trials. Problems include poor reporting, and uncritical analysis and 
interpretation of PRO scores. Research needs include identifying and recommending a set of 
PROs for use in asthma clinical research and providing guidance for researchers on the 
application, analysis and interpretation of PRO measures in clinical trials.  
 
Keywords   ▪ Asthma-related quality of life ▪ Health-related quality of life ▪ Patient outcome 
assessments ▪ Symptom scores ▪ Inhaled corticosteroids ▪ Beta-2 agonists 
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Abbreviations 
ACQ   Asthma control questionnaire 
ACQ-5  Five-question version of the asthma control questionnaire 
AQLQ  Asthma quality of life questionnaire 
AQLQ(S)  Standardised version of the asthma quality of life questionnaire 
HRQoL Health-related quality of life 
ICS   Inhaled corticosteroid(s) 
LABA     Long-acting beta-2 agonist(s) 
LWA  Living with asthma questionnaire 
MID  Minimal important (clinically significant) difference 
NICE  National Institute for Health and Clinical Excellence 
miniAQLQ Short version of the AQLQ 
PAQLQ(S) Standardised version of the paediatric asthma quality of life questionnaire 
PRO(s)  Patient reported outcome(s) 
RCT(s)    Randomised controlled trial(s) 
SABA  Short-acting beta-2 agonist(s) 
%SFD  Proportion of a population with symptom-free days or nights 
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Introduction 
Asthma is a chronic inflammatory disorder of the airways that affects 300 million people 
worldwide. Inflammatory processes and constriction of the smooth muscle in airway walls lead 
to coughing, wheezing, chest tightness, and dyspnea (shortness of breath) which can interfere 
with the daily lives of patients, including sleeplessness, daytime fatigue, reduced activity levels 
and school and work absenteeism. Asthma therapy aims to improve the patient’s quality of life 
by controlling symptoms, preventing exacerbations, attaining normal airway function and 
maintaining normal activity levels. Daily medication to control the underlying inflammation and 
prevent symptoms and exacerbations typically involves inhaled corticosteroids (ICS) as a 
'preventer' therapy which can be supplemented if necessary with inhaled long acting beta-2 
agonists (LABA). Short-acting beta-2 agonist (SABA) ‘reliever’ medication may also be used. 
 
Asthma severity and control have traditionally been assessed using objective measures such as 
lung function, SABA use and airway inflammation, but these clinical outcomes do not always 
reflect how patients function and feel [1, 2]. Measurements of lung function may correlate 
poorly with patients’ self-reported symptoms [3-11] and quality of life [1, 2, 12], meaning that 
perception of the disease may differ between patients and clinicians, with implications for 
therapeutic decisions and adherence to treatment [13]. International asthma management 
guidelines recommend that assessments of asthma therapy should include patients’ self-reported 
outcomes [14]. 
 
Patient-reported outcomes (PROs) assessed in asthma clinical trials include symptom scores [3] 
and health-related quality of life (HRQoL) scores [12]. HRQoL is a patient’s subjective 
perception of the impact of their disease and its treatment(s) on their daily life, physical, 
psychological and social functioning and well-being [15, 16]. PRO measures usually consist of 
diaries or questionnaires which are completed by clinical trial participants (or their 
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representatives). An ‘item’ refers to a single question within a PRO instrument (e.g. ‘how do 
you feel?’) and a ‘scale’ is the available categories for expressing the response to the question 
(e.g. ‘very good’, ‘good’, ‘bad’, ‘very bad’) [15]. ‘Score-based PROs’ are those for which each 
response category of the scale is assigned a numeric value (e.g. very good=0; good=1; bad=2; 
very bad=3) that can be used to calculate a score.  
 
Validation of PROs is the process of ensuring that a PRO instrument actually measures what it 
claims to, in an unbiased way. Key psychometric properties that should be reported to ensure 
validity of  PROs include (inter alia): construct validity (whether a PRO actually reflects and 
measures the underlying theoretical concept); internal consistency (the extent to which all of the 
items of a PRO measure the underlying theoretical concept); test-retest reliability 
(reproducibility of PRO results when applied repeatedly to the same patient group); discriminant 
ability (whether a PRO can differentiate between patients with varying degrees of disease 
severity); and responsiveness (ability of a PRO to detect clinically important changes over time) 
[17, 18].  
 
Numerous asthma-specific assessment instruments for assessing patient-reported symptoms and 
quality of life have been validated for their construct validity, internal consistency, test-retest 
reliability, discriminant ability and/or responsiveness (Supplementary Table S1). The use of 
PRO measures has not been without controversy, however. In 1998, Juniper [19] observed that, 
in respiratory and allergy clinical trials, patients’ clinical status, functional status, and HRQoL 
were interpreted only in terms of their statistical significance, with little or no consideration of 
clinical relevance. One way of assessing clinical significance is to determine the minimal 
important difference (MID) for a PRO measure (defined as the smallest difference in score in the 
domain of interest that patients perceive as beneficial and would mandate (subject to side effects 
and cost) a change in the patient’s management [19]). A narrative review published in 1994 [5] 
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and a systematic review published in 2000 [6] found different instruments were being used for 
assessing symptoms in asthma clinical trials, but with little consistency across the studies, and 
various non-validated and apparently unique instruments in use. The systematic review [6] 
included 21 studies, not restricted to randomised controlled trials (RCTs), that analysed 
correlations between symptoms and lung function, but excluded measures of HRQoL. 
Interpretation of PRO scores has also been the subject of a long-term debate about whether 
scores should be treated as ordinal or continuous variables [20-23].  
 
It is unclear how the use of PROs in asthma clinical trials has changed since these earlier 
reviews, and whether the previous criticisms about validation, and clinical and statistical 
interpretation still apply.  Our objective was to comprehensively and critically investigate the 
types of PRO that are used for assessing symptoms and HRQoL in asthma clinical trials and 
how they are analysed and interpreted in the context of decision making for asthma therapy.  
                           
Methods 
 
As a source of evidence we included RCTs identified from two peer-reviewed systematic 
reviews of the clinical effectiveness and safety of ICS and LABA for asthma treatment in adults 
[24] and children [25].  These reviews are relevant to clinical decision making as they had been 
conducted to inform clinical guidance issued by the National Institute for Health and Clinical 
Excellence (NICE) in England and Wales on asthma management in adults [26] and children 
[27]. The systematic reviews are reported in full in the original reports [24, 25] and summarised 
in a related publication [28]. Eligible populations were adults and children with asthma but 
excluding chronic obstructive pulmonary disease or any other respiratory co-morbidity. 
Interventions were any of five individual ICS  or ICS combined with any of two LABA. 
Comparators were any of these drugs compared head-to-head or against a placebo. Required 
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outcomes were at least one of the following: a measure of lung function; nocturnal awakening; 
symptom scores; the proportion of patients with symptom-free days or nights (%SFD); HRQoL 
scores; reliever medication use; exacerbations; adverse events. 
 
Systematic review of PROs 
 
The systematic review we report here is an independent extraction and appraisal of data on 
PROs from the peer-reviewed research papers reporting asthma RCTs that were included in the 
two primary systematic reviews [24, 25]. Papers that met the inclusion criteria for the original 
systematic reviews were first scrutinised to ascertain the range of asthma-specific PROs they 
reported for symptoms and HRQoL and the level of detail reported. Preliminary scrutiny of the 
papers identified relatively little information about the psychometric testing of PRO instruments. 
For this reason we did not apply a formal appraisal tool to assess in detail the different 
dimensions of PRO validity. Instead, we documented whether RCTs considered the existing 
validity of any PRO instruments used, whether they conducted a validation for their specific trial 
settings, and whether any psychometric information was reported.  
 
Each paper was screened systematically and the following information on the PRO assessment 
instruments was collected: the constructs (symptoms or HRQoL) and domains (aspects of 
symptoms or HRQoL) being assessed; the number of PRO items and, for each item, the wording 
and numbering of the scale used (excluding measures that comprised only dichotomous (yes/no) 
response categories); any psychometric properties reported; any consideration of the clinical 
relevance of the assessment instruments (e.g. MID or any other assessment of discriminant 
ability). We also recorded: the timing of assessments (as asthma symptoms may exhibit diurnal 
variation [29]); whether symptoms were presented as scores at baseline and follow up; and any 
explanations given for the statistical analysis used for PROs.  The information was extracted by 
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one reviewer (GKF) and was checked for a random subset of 20 RCTs independently by a 
second reviewer (JS). Reviewer agreement was estimated using Cohen’s free-marginal kappa 
[30].  
 
To classify the different PROs according to the symptom domains that they included, we entered 
the symptom domains as reported for each PRO into a spreadsheet and grouped together all 
PROs that had the same combinations of symptom domains. This enabled a classification of 
symptom assessment instruments that captured all the symptom domains reported in the asthma 
RCTs.  We did not develop a pre-defined PRO classification system because it is unclear in 
asthma research which domains are considered most important by researchers, and such a 
system might miss aspects of PROs reported in the asthma trials.  
 
We compared the actual usage of asthma-specific PRO instruments in the asthma RCTs with an 
estimate of the likely availability of relevant validated instruments for assessing asthma 
symptoms and HRQoL for the time period covered by our systematic review. This was based on 
two assumptions. First, we assumed that a list of 33 asthma-specific PRO instruments 
(Supplementary Table S1) represents the majority of relevant PROs that would have been 
available. This list of PROs was developed by searching two PRO databases [31, 32], 
supplemented by a general internet search and scrutiny of the text and reference lists of the peer-
reviewed papers that reported the asthma RCTs. Second, we assumed that each of the PRO 
instruments would have been readily available for use by researchers from the year of the first 
publication of the validated version of the instrument (Supplementary Table S1). 
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Results 
 
Together, the primary systematic reviews [24, 25]
 
included 87 RCTs [33-120] (Table 1) 
published during 1985 to 2006, of which 70 were on adults, 16 on children, and one on both 
adults and children. Score-based PROs were measured in 79 RCTs. In 78 of these (99%) they 
assessed symptoms and in seven (9%) they assessed asthma-related quality of life. Reviewer 
agreement for data collection was 95% (range 90-100% for individual variables; Cohen’s free-
marginal kappa [30] ≥ 0.80).  
 
Symptom scores 
 
Symptom measures reported in the 78 RCTs could be classified into 15 distinct types according 
to the domains that they included (Table 2). A description of the symptom measures, indicating 
how we assigned them to each class, is provided in Appendix A. The most frequently reported 
symptom measures assessed asthma severity (19 RCTs) (24%), a combination of asthma 
severity and activity (16 RCTs) (21%), night waking due to asthma severity (15 RCTs) (19%), a 
combination of asthma severity, symptom duration and activity (12 RCTs) (15%), or the specific 
symptoms of cough, dyspnea or wheeze (11, 12 and 12 RCTs respectively) (14-15%). Twelve 
RCTs (15%) did not specify which symptom domains they were measuring. Half (39) of the 
RCTs (50%) used a single instrument to assess symptoms, 26 RCTs (33%) used two 
instruments, 10 RCTs (13%) used three instruments, and the remaining three RCTs (4%) used 
four instruments (data not shown). Although functional status (a patient’s ability to perform 
normal activities) and symptoms are distinct domains [121], these were always combined in a 
single item with a single response scale (e.g. Tables A7-A8 in Appendix A). 
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The majority (73) of the 78 RCTs (94%) specified the time of day at which symptoms were 
measured (Table 2). However, none of the RCTs defined what they meant by ‘day’, ‘night’, 
‘morning’, ‘evening’ or ‘daily’ periods (i.e. the duration, start and end times of these periods 
were not specified). Although circadian variation in asthma is well known [29], none of the 
RCTs explained why they measured asthma symptoms at these times, or provided any clinical 
interpretation of the scores in the context of temporal variations in asthma. 
 
PRO instruments which assessed the same symptom domains often differed in the numbering 
and wording of their response categories (Appendix A). In eight of the 78 RCTs (10%) the 
number of response categories was not reported; in 14 RCTs (18%) the wording of the response 
categories was not reported; and in 30 RCTs (38%) the wording of response categories was 
reported only for some of the categories. In most (74) of the 78 RCTs (95%) it was unclear 
whether the symptom instruments reported were exactly as administered to patients, or a 
paraphrased or summarised version. The four RCTs that did report the wording of symptom 
assessments as administered to patients used previously validated scales (Table 1) (symptoms-
only sections of the asthma control questionnaire (ACQ) and the mini asthma quality of life 
questionnaire (miniAQLQ), and scores from a symptom diary scale that had been developed and 
validated by Santanello et al. [122]). The remaining 74 RCTs did not provide any information 
about how their symptom assessment instruments were developed, any psychometric properties 
of the instruments, whether any aspects of validation had been attempted, or why they were 
selected for use in the asthma RCTs.  
 
Due to inconsistency in the reporting of PRO instruments and subtle differences in the wording 
of response categories (Appendix A) it was difficult to determine exactly how many individual 
instruments were used. For each combination of symptom domains we estimated the likely 
lower and upper limits for the number of individual symptom score instruments used (Table 2), 
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by assuming that instruments of uncertain similarity could be grouped together, and we 
estimated upper limits by assuming that instruments of uncertain similarity were each distinct 
(Appendix A). Although a subjective classification, it demonstrates uncertainty in the number of 
distinct PROs used to assess asthma symptoms. 
 
Of the 78 RCTs that reported measuring symptom scores, 35 RCTs (45%) did not present any 
scores for baseline or follow up (Table 1). Symptom scores were reported for baseline only in 
three of the 78 RCTs (4%); for both baseline and follow up in 22 RCTs (28%); for baseline and 
the change from baseline to follow up in 14 RCTs (18%); only for the change from baseline to 
follow up in six RCTs (8%); and for follow up alone in four RCTs (5%). Symptoms were 
summarised as the proportion of patients with symptom-free days or nights (%SFD) in 48 of the 
78 RCTs (62%).  
 
Of 52 RCTs that did not report symptom scores at follow up, 39 (75%) reported %SFD. Of 26 
RCTs that did report symptom scores at follow up, nine (35%) reported %SFD. The reporting of 
symptom scores and %SFD at follow up appear not to be independent (χ2=11.94; p=0.001; post-
hoc test). 
 
Asthma HRQoL scores 
 
Seven of the 78 RCTs (9%) assessed HRQoL (Table 1). Of these seven, five [82, 94, 97, 103, 
120] used versions of the asthma quality of life questionnaire (AQLQ); one [55] used the living 
with asthma questionnaire (LWA); and one [107] used a generic HRQoL instrument, the SF-36, 
which had been demonstrated to be valid in asthma research. Versions of the AQLQ [123-125], 
LWA [126] and SF-36 [127] have been validated in certain asthma populations and settings in 
terms of their construct validity, test-retest reliability, responsiveness and (except for the LWA) 
 12 
internal consistency. The five RCTs that employed versions of the AQLQ used the original 
AQLQ, a validated German version of the AQLQ, the miniAQLQ, AQLQ(S), and PAQLQ(S). 
Four of the seven RCTs that assessed HRQoL [82, 94, 103, 120] discussed their findings in 
terms of the pre-established MID for these instruments (for each version of the AQLQ a score 
difference of ≥ 0.5). One RCT [97] did not mention the MID but found that AQLQ scores were 
close to the maximum possible and interpreted this to imply clinical relevance to the patients. 
One RCT [107] stated that differences in scores were clinically relevant but provided no 
explanation. The remaining RCT that used the LWA questionnaire did not discuss scores in 
terms of clinical significance. An RCT [82] that used the miniAQLQ reported a trial-specific 
cultural and linguistic adaptation of the instrument to the specific population included in the 
RCT but provided no details. The remaining RCTs did not check or adjust the instruments for 
relevance to their particular trial settings.  
 
Overview of PRO scores 
    
Taking symptom scores and asthma HRQoL scores together, only nine of the 79 RCTs that 
reported PROs (11%) used instruments that had been previously validated (Table 1). No 
validated PROs were used in the asthma RCTs before 1998. There is evidence for an increase in 
the number of validated PRO instruments used after 2000 (Fig. 1). However, the proportion of 
RCTs that used validated PROs did not reach 30% in any of the last six years covered by our 
systematic review (2000-2006). Most (56) of the 79 RCTs that measured PROs (71%) were 
published after 1995, when at least 14 validated asthma-specific instruments would have been 
available to researchers (Fig. 1). For validated PRO instruments used in asthma RCTs, the time 
lag between first publication of the PRO instrument and publication of the asthma RCT ranged 
from 3 to 12 years, with the shortest lag times being three years for the miniAQLQ (study 50 in 
Table 1) and four years for the symptom scales of ACQ (study 68) and ACQ-5 (study 70). None 
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of the RCTs provided any reasons for selecting or rejecting particular PROs, although the choice 
of instruments did appear appropriate for the populations included, with adult-validated 
instruments and a paediatric-validated instrument being applied, respectively, to adult and child 
populations.  
 
Statistical interpretation 
 
In one RCT (study 68 in Table 1) the ACQ symptom score was the primary outcome measure, 
with statistical power reported for detecting a score difference ≥0.5 (i.e. the MID). All the other 
reported PROs were secondary outcome measures for which the statistical power of PRO score 
comparisons was not reported. Statistical analyses of differences in symptom scores between 
intervention groups were reported in 51 of the 78 trials (65%), of which 23 used non-parametric 
and 28 used parametric approaches. The remaining 27 trials either did not report any statistical 
analyses (20 trials) or reported several analysis methods but did not explain to which outcomes 
they applied (7 trials). All comparisons of asthma HRQoL scores used parametric statistical 
approaches. However, only one of the 78 RCTs justified the choice of an analysis approach, 
based on an assumption that symptom scores data would have been normally distributed (study 
20). None of the trials acknowledged that there is a debate about how to interpret and analyse 
ordinal symptoms data. 
 
Clinical interpretation 
 
The majority of the RCTs that reported PROs did not provide any clinical interpretation of the 
PRO scores. Clinical interpretation was based primarily on comparing changes in scores against 
a pre-established MID for versions of the ACQ or AQLQ. Thus, for symptom scores, only those 
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based on subscales of the ACQ, ACQ-5 or miniAQLQ (3/78 RCTs [4%]) were presented with 
any clinical interpretation (Table 1).  
 
Discussion  
 
Symptom scores are frequently measured in asthma RCTs but without validation or 
consideration of their psychometric properties. In contrast, measures of HRQoL have been 
validated but used infrequently in asthma RCTs, although their usage has increased. Most of the 
asthma RCTs were published after 1995 when at least 14 validated asthma PRO instruments 
appear to have been available. Given that RCTs usually take several years to develop, conduct 
and report, our estimated lag of 3 or 4 years between validated versions of the miniAQLQ, ACQ 
and ACQ-5 being published and their use being reported in asthma RCT papers suggests that at 
least some PROs can be readily utilised by researchers soon after they are published. Our 
estimates do not take into account exact dates of publication, pre-publication awareness of PROs 
by researchers, and accessibility of PRO instruments (e.g. differences in publication availability 
between open/limited access and high/low impact journals). Such information is difficult to 
acquire and would require a dedicated research effort, though it could help in understanding how 
to improve the utilisation of validated PROs by clinical researchers.  
 
It seems odd that 67% of RCTs that measured symptom scores did not report any quantitative 
scores at follow up. A statistically significant association between reporting symptom scores and 
%SFD at follow up indicates that %SFD were more likely to be reported in RCTs which did not 
report symptom scores than in RCTs which did (suggesting a tendency to report %SFD instead 
of scores). Converting symptom severity to the proportion of symptom-free patients might 
discard useful clinical information. It is unclear whether this should be viewed as selective 
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reporting or whether there were practical reasons for treating symptom scores in this way, as no 
explanations were provided. 
 
Symptom perception differs among individuals, is sensitive to personality type [128] and 
changes in emotions [129], and the predicate (e.g. ‘mild’ or ‘severe’) may mean different things 
to different people [21]. Even if symptom scales appear to be similar (Appendix A), there may 
be differences in what they actually measure [21]. The use of validated symptom score 
instruments in asthma research would clarify whether similar PRO instruments actually measure 
the same constructs and elicit consistent patient responses; and whether the instruments can be 
grouped together and their symptom scores pooled meaningfully in meta-analyses.  
 
Statistical analysis approaches used in over one third of the studies that reported symptom scores 
were ambiguous, highlighting a need for improved rigour in statistical reporting. Although no 
clear ‘right’ or ‘wrong’ way to analyse PRO scores has yet emerged, further research progress in 
this area will be hindered if studies fail to clearly report the methods and rationale of their 
statistical analyses. Ideally, these should be justified at the design stage of clinical trials [22]. 
 
Juniper’s observation over a decade ago [19] that respiratory and allergy clinical trials focus on 
statistical significance rather than clinical meaning of PRO scores evidently still holds true for 
asthma symptom scores, although asthma HRQoL scores were mostly interpreted in terms of a 
previously defined MID. No trials however considered whether a MID based on a different 
population and setting would be relevant to their particular patients and trial conditions. Of 
particular concern with non-validated symptom scores is that, if the number of patients analysed 
is large, even small differences in scores may achieve statistical significance.  
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Conclusions 
 
There appears to be a need for guidance to encourage clinical researchers to use validated PRO 
measures when assessing asthma symptoms; to improve the reporting of PRO measures that are 
used; and to improve critical consideration of their statistical and clinical interpretation. 
Researchers should be encouraged to justify their reasons for selecting or rejecting particular 
PRO measures to enable identification of those instruments likely to be most relevant and useful 
in clinical trials. Validated asthma control or HRQoL instruments (e.g. versions of the ACQ and 
AQLQ) already include activity and symptoms domains for which some psychometric properties 
are available. Research effort could focus on further developing these PRO measures, building 
on the existing evidence base of psychometric information (e.g. testing for validity in a wider 
range of populations and settings), rather than developing new PRO measures that would be 
poorly supported by psychometric information. Advantages of focusing on a smaller set of 
validated PRO measures are: databases of psychometric properties could be developed for a 
wider range of populations and settings; clinical relevance could be more thoroughly evaluated 
(e.g. using different approaches to determine MID in different settings); and harmonisation of 
measures would benefit evidence syntheses, including clarification of which symptom measures 
may legitimately be pooled in meta analyses.  
 
To improve the use of PRO measures in asthma research, our systematic review suggests there 
are two key research needs: (1) To identify and recommend an appropriate set of validated PRO 
measures for use in asthma research (the range of available measures should be sufficient to 
cover all relevant symptom domains (e.g. Table 2) and populations, e.g. children and adults), 
preferably with  guidance for researchers on how to select appropriate measures for addressing 
different types of clinical question (e.g. a checklist for identifying appropriate HRQoL 
outcomes, as has been developed in cancer research [130]).  (2) To provide recommendations 
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for improving the ways that PRO measures are applied, analysed, interpreted and reported in 
clinical trials. These research requirements would be relevant to a range of respiratory and 
allergy societies and stakeholders (including clinicians, academic researchers, statisticians, 
psychologists, journal editors and pharmaceutical companies). It might be appropriate that they 
are addressed by an international working group, particularly as there is currently no clear 
international guidance on how PRO measures should be selected, applied, analysed, and 
interpreted in asthma research or related areas of respiratory health. 
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Online Supplementary Table 
Table S1: Examples and characteristics of validated asthma-specific PRO assessment 
instruments for symptoms and HRQoL 
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Figure legends 
Fig. 1. Randomised controlled trials (RCTs) of asthma inhalers included in the review which 
were published during 1985 to 2006. Validated patient reported outcomes (PROs) are defined as 
those which had been evaluated for their internal consistency, test-retest reliability, construct 
validity, discriminant ability, and/or responsiveness. Also shown are (in box) an estimate of the 
numbers of validated asthma PROs available during the study period (from Supplementary 
Table S1) and (arrowed) the years in which nine validated PROs used in the asthma RCTs were 
first published. 
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Table 1. Characteristics of patient-reported outcome (PRO) assessments in 87 RCTs of inhaled asthma medications S: symptoms; HRQoL: health-
related quality of life; --- not applicable). Asterisks indicate a random subset of 20 RCTs that were assessed for reviewer data extraction 
agreement.  
 
Study number, authors, publication year 
and [reference]  
 
(Population: 
Ad
: adults; 
Ch
: children) 
PRO assessed 
(S=symptoms) 
PRO scores reported 
for baseline 
PRO scores reported 
for follow up 
Symptom-free 
days or nights 
reported at 
follow up 
Reported validation of 
the PRO assessment 
instrument 
Clinical significance of 
PRO scores discussed 
1. Rafferty et al. 1985  [33] 
Ad
   yes: S no yes no no no 
2. Ebden et al. 1986*  [34]
 Ad
 yes: S no yes no no no 
3. Bisgaard et al. 1998  [35] 
Ch
 no --- --- --- --- --- 
4. Pedersen & Fuglsang  1988  [36] 
Ch
 no --- --- --- --- --- 
5. Fitzgerald et al. 1988*  [37] 
Ch
 yes: S no yes no no no 
6. Fabbri et al. 1993*  [38] 
Ad
 yes: S no no     yes no no 
7. Barnes et al. 1993  [39]
 Ad
 yes: S no no     yes no no 
8. Lundback et al. 1993  [40]
 Ad
 yes: S no no 
A
  yes no no 
9. Gustaffson et al. 1993  [41] 
Ch
 yes: S no no     yes no no 
10. Langdon & Capsey 1994  [42]
 Ad
 yes: S no no      yes no no 
11. Langdon & Thompson 1994  [43]
 Ad
 yes: S yes yes no no no 
12. Boe et al. 1994*  [44]
 Ad
 yes: S yes yes no no no 
13. Tjwa 1995  [45]
 Ad
  yes: S no yes no no no 
14. Connolly 1995  [46]
 Ad
 yes: S no no     yes no no 
15. Bootsma et al. 1995*  [47]
 Ad
  yes: S yes yes no no no 
16. Ayres et al. 1995  [48]
 Ad
  yes: S no no 
B
   yes no no 
17. Lorentzen et al. 1996  [49]
 Ad
  yes: S no no 
C
  yes no no 
18. Ringdal et al. 1996  [50]
 Ad
  yes: S no no      yes no no 
19. Hoekx et al. 1996  [51] 
Ch
 yes: S no no      yes no no 
20. Basran et al. 1997  [52]
 Ad
  yes: S yes yes no no no 
21. Agertoft & Pedersen 1997  [53]
 Ch
  yes: S yes yes no no no 
22. Yiallouros et al. 1997  [54]
 Ch
  yes: S no no     yes no no 
23. Pauwels et al. 1998  [55]
 Ad
  yes: S, HRQoL S=no  HRQoL=no S=no  HRQoL=yes yes   S=no  HRQoL=yes 
D
  no 
24. Bateman et al. 1998  [56]
 Ad
 yes: S no no 
C
   yes no no 
25. Dal Negro et al. 1999  [57] 
Ad
 yes: S yes yes no no no 
26. Raphael et al. 1999  [58]
 Ad
  yes: S yes no 
A
 yes no no 
27. Egan et al. 1999*  [59]
 Ad
  no --- --- --- --- --- 
28. Malo et al. 1999  [60]
 Ad
 no --- --- --- --- --- 
29. Heinig et al. 1999*  [61]
 Ad
  yes: S no no 
E
   yes no no 
30. Hughes et al. 1999  [62]
 Ad
  no --- --- --- --- --- 
31. Aubier et al. 1999  [63]
 Ad
 yes: S no no  yes no no 
32. Chapman et al. 1999  [64]
 Ad
  yes: S no no  yes no no 
33. Rao et al. 1999*  [65] 
Ch
 yes: S no no no no no 
34. Ferguson et al. 1999  [66]
 Ch
  yes: S no no 
C, E
   yes no no 
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35. Jäger et al. 2000  [67]
 Ad
  yes: S no no
 F
 no no no 
36. Medici et al. 2000  [68]
 Ad
 no --- --- --- --- --- 
37. Bousquet et al. 2000*  [69]
 Ad
  yes: S yes no no no no 
38. Jenkins et al. 2000  [70]
 Ad
  yes: S no no  yes no no 
39. Kavuru et al. 2000*  [71]
 Ad
 yes: S yes no 
A
 yes no no 
40. Shapiro et al. 2000  [72]
 Ad
  yes: S yes no 
A
 yes no no 
41. van den Berg et al. 2000  [73]
 Ch
  yes: S no no   yes no no 
42. O'Connor et al. 2001  [74]
 Ad
  yes: S yes no 
A
 no no no 
43. Aubier et al. 2001  [75]
 Ad
  yes: S no no   yes no no 
44. Johansson et al. 2001  [76]
 Ad
 yes: S no no   yes no no 
45. Zetterström et al. 2001  [77]
 Ad
  yes: S yes no 
A
 yes no no 
46. de Benedictis et al. 2001  [78]
 Ch
  yes: S no no no no no 
47. Szefler et al. 2002*  [79] 
Ad
 yes: S yes yes no no no 
48. Ige et al. 2002  [80]
 Ad
  yes: S yes yes no no no 
49. Ringdal et al. 2002  [81]
 Ad
  yes: S no no 
C
 yes no no 
50. Rosenhall et al. 2002  [82]
 Ad
  yes: S, HRQoL S=yes  HRQoL=yes S=no 
A
  HRQoL=no
 A
 no S=yes 
G  
HRQoL=yes 
H
  S=yes 
I
   HRQoL=yes 
I
 
51. Kannisto et al. 2002*  [83, 84]
 Ch
  no --- --- --- --- --- 
52. Tal et al. 2002  [85]
 Ch
  yes: S yes no 
A
 yes no no 
53. Corren et al. 2003  [86]
 Ad
  yes: S yes no 
A
 yes no no 
54. Kuna  2003  [87]
 Ad
  yes: S yes yes no no no 
55. Busse et al. 2003  [88]
 Ad
  yes: S yes no 
A
 yes no no 
56. Bateman et al. 2003  [89]
 Ad
  yes: S no no   yes no no 
57. Lalloo et al. 2003  [90]
 Ad
  yes: S no no 
A
   yes no no 
58. Buhl et al. 2003  [91]
 Ad
  yes: S yes yes yes no no 
59. Parakh et al. 2004  [92]
 Ad
 yes: S yes yes no no no 
60. Prasad et al. 2004  [93]
 Ad
  yes: S no no 
A
 no no no 
61. Bergmann et al. 2004*  [94]
 Ad
  yes: S, HRQoL S=yes   HRQoL=no S=no
 A
  HRQoL=no
 A
 yes S=no  HRQoL=yes 
H 
 S=no  HRQoL=yes
 I
 
62. Zhong et al. 2004  [95]
 Ad
  yes: S yes no yes no no 
63. Schiccitano et al. 2004  [96]
 Ad
  yes: S yes yes yes no no 
64. Bateman et al. 2004  [97]
 Ad
  yes: S, HRQoL S=yes   HRQoL=no S=no  HRQoL=yes no S=no  HRQoL=yes 
D 
 S=no  HRQoL=yes 
J
 
65. Aalbers et al. 2004  [98]
 Ad
  yes: S yes yes no no no 
66. Niphadkar et al. 2005*  [99]
 Ad
  yes: S no no  yes no no 
67. Kaur et al. 2005  [100]
 Ad
  no --- --- --- --- --- 
68. Molimard et al. 2005  [101]
 Ad
  yes: S no no 
A
 no yes 
K
 yes 
I
 
69. FitzGerald et al. 2005  [102]
 Ad
  yes: S yes yes  yes no no 
70. Vogelmeier et al. 2005*  [103]
 Ad
  yes: S, HRQoL
 
 S=yes   HRQoL=yes S=no
 A  
HRQoL=no
 A
 no S=yes 
K  
HRQoL=yes 
L
  S=yes 
I
   HRQoL=yes
 I
 
71. O'Byrne et al. 2005*  [104] 
Ad+Ch
 yes: S yes yes yes no no 
72. Altintas et al. 2005  [105] 
Ch
 yes: S yes yes no no no 
73. Malone et al. 2005  [106]
 Ch
 yes: S no no no no no 
74. Pohl et al. 2006*  [107] 
Ad
 yes: HRQoL yes yes no yes M no N 
75. Buhl et al. 2006  [108]
 Ad
 yes: S yes no 
A
 yes no no 
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76. Koopmans et al. 2006  [109]
 Ad
  yes: S yes no 
A
 no no no 
77. Lundback et al. 2006*  [110]
 Ad
  yes: S no no   yes no no 
78. Kuna et al. 2006  [111]
 Ad
  yes: S no no  yes no no 
79. Nathan et al. 2006  [112]
 Ad
 yes: S yes no 
A
   yes no no 
80. Dahl et al. 2006  [113]
 Ad
  yes: S yes yes
 
   yes no no 
81. Jenkins et al. 2006*  [114]
 Ad
  yes: S no no 
A  
  yes no no 
82. Bateman et al. 2006  [115]
 Ad
  yes: S yes yes yes no no 
83. Zietlowski et al. 2006  [116]
 Ad
 yes: S yes yes no no no 
84. Horiguchi et al. 2006*  [117]
 Ad
 yes: S no no 
A
 no yes
 O no 
85. Rabe et al. 2006  [118]
 Ad
  yes: S yes yes  yes no no 
86. Jarjour et al. 2006  [119]
 Ad
 yes: S yes yes yes no no 
87. Pohunek et al. 2006  [120] 
Ch
 yes: S, HRQoL S=yes  HRQoL=yes S=yes   HRQoL=yes yes S=no  HRQoL=yes 
P
 S=no  HRQoL=yes 
I
 
A
 Changes in scores but not absolute scores were reported. 
B
 Reported the proportion of patients with scores improving or worsening 
C
 Reported % of patients or time with a specified score, not scores per se 
D 
 The Living with asthma questionnaire (LWA) (for details of this instrument see Table S1) 
E
 Reported statistical significance of differences in scores (p-values), not scores themselves 
F
 Reported mean % of the maximum score 
G 
The symptoms scale of the miniAQLQ, which was reported separately from the overall miniAQLQ score (for details of this instrument see Table S1) 
H 
A version of the asthma quality of life questionnaire (AQLQ) (for details of this instrument see Table S1) 
I 
Referred to the previously-established minimum important difference for this instrument (a change of ≥ 0.5) 
J 
As scores were close to the maximum possible they were assumed to be clinically relevant (no further explanation given) 
K
 The symptoms scale of the asthma control questionnaire (ACQ), which was reported separately from the overall ACQ score. 
L  
The standardised version of the asthma quality of life questionnaire (AQLQ(S)) (for details of this instrument see Table S1) 
M 
The SF-36 generic instrument which has previously been validated in asthma research (for details of this instrument see Table S1) 
N 
Stated that differences in scores were clinically relevant but no explanation provided 
O
 Asthma symptom diary reported and validated by Santanello et al. (for details of this instrument see Table S1) 
P
 The pediatric asthma quality of life questionnaire (PAQLQ(S)) (for details of this instrument see Table S1). 
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Table 2. The number of studies and (in brackets) the number of different PRO assessment instruments used in 78 randomised controlled trials of 
inhaled asthma medications classified according to the symptom domains they included and the timing of the assessments.  Ranges in brackets 
depict uncertainty in the number of distinct instruments that were used (for further explanation see the text and Appendix A) -- : not applicable. 
 
Domain(s) included in assessment instrument Timing of assessment Total 
number 
of 
RCTs
A
 Day Night AM PM ‘Daily’ 24h 
After 
exercise 
Timing 
not 
reported 
Asthma severity 11 (2-3) 9 (2-3) 3 (2-3) 2 (1-2) 3 (2) 0 0 2 (1-2) 19 
Asthma severity + activity 16 (3-14) 0 0 0 0 0 0 0 16 
Asthma severity + symptom duration + activity 12 (3-12) 0 0 0 0 0 0 0 12 
Cough 4 (1-3) 3 (1-2) 3 (1) 2 (1) 2 (1) 2 (1-2) 0 0 11 
Dyspnea 4 (3) 3 (2) 3 (1) 2 (1) 2 (1) 2 (1-2) 0 1 12 
Wheeze 5 (2-4) 3 (1-2) 3 (1) 2 (1) 1 2 (1-2) 0 0 12 
Cough + dyspnea 0 0 0 0 1 0 0 0 1 
Cough + dyspnea + wheeze 0 0 0 0 1 0 0 0 1 
Dyspnea + wheeze + activity 2 (1-2) 0 0 0 0 0 2 (1-2) 0 4 
Unspecified symptoms 6 (3-6) 6 (3-6) 1 1 3 (2-3) 0 0 2 (1-2) 12 
Waking due to asthma severity -- 15 (2-15) -- -- -- -- -- -- 15 
Waking due to cough or asthma -- 2 (1) -- -- -- -- -- -- 2 
Waking due to cough, dyspnea or wheeze -- 4 (1-2) -- -- -- -- -- -- 4 
Waking due to unspecified symptoms -- 10 (4-10) -- -- -- -- -- -- 10 
Waking + dyspnea + wheeze + asthma severity + 
activity  
-- -- -- -- -- 2 (2) -- -- 2 
A
 The total number of RCTs may be less than the number of RCTs in each row of the table as individual RCTs often included more than one 
assessment time; the total in the right-hand column exceeds 78 as some RCTs assessed more than one symptom domain. 
 
 
